// App-Quantinova.ai

BSH19‐PO‐125 : A Phase 1 study to determine maximum tolerated dose of sublingual fentanyl in combination with oral oxycodone for hospital management of an acute painful crisis in adolescents and adults with sickle cell disease

Researchers

Presenter

  • P. Telfer

Principal Investigators

  • B. Kaya

  • F. Barroso

  • R. Nzouakou

  • A. Osias

  • B. Bloom

  • I. Skene

  • O. Boulton

  • J. Challands

Medical Centers

  • Centre for Genomics and Child Health, Blizard Institute, Queen Mary University of London, London, United Kingdom

  • Haematology, Barts Health NHS Trust

  • Department of Acute and Emergency Medicine

  • Emergency Medicine Clinical Trials Unit

  • Anaesthetics, Royal London Hospital, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

  • Pulmonary/Respiratory Diseases

  • Blood/haematological Diseases

  • Endocrine/metabolic Diseases (ME)

Disease

  • Acute chest syndrome

  • Sickle cell anemia

  • Constipation

Biomarkers

  • Stearoyl-CoA desaturase

Drug/Treatment

  • Oxycodone

  • Fentanyl

  • Epimorph

  • Opiate

Outcome

  • N/A

Study Design

  • Randomized

  • Fixed Dose

  • Controlled

  • Dose Escalation

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved